You're late to the game. I've been saying it for at least 5. Management is not stupid enough not to understand that - the problem is there is no clear path to FDA data, and they know it.
If I'm an idiot, why is the stock at $3? Could it be because no one in their right mind cares about a few million in sales without a path towards proving that the device actually works?
There has to be actual news for him to talk about. And they have nothing. No significant clinical data. No material progress on sales (because they don't have the clinical data).
So what exactly do you expect him to talk about? Some anecdotal patient cases that no professional investor would ever care about?
Get a grip. I've been saying this for years. It's still true